News & Updates

Evidence from a large population-based study shows no consistent association between an increased risk of cancer and exposure to antihypertensive drugs.

Women with early-stage breast cancer (BC) entering randomized controlled trials (RCTs) after the 2000s have reduced rates of distant recurrence vs the 1990s, a patient-level pooled analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) has shown. 

The novel, small-molecule, orally administered third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) olverembatinib is well-tolerated and shows promising antitumour activity in patients with heavily pretreated chronic-phase chronic myeloid leukaemia (CML), according to the results of a phase 1B study.

A cohort study conducted by researchers from the University of Hong Kong (HKU) reports a complete response (CR) rate of 46.0 percent among patients with locally advanced, unresectable hepatocellular carcinoma (HCC) who were treated with locoregional therapy (LRT) plus immunotherapy (IO) and a 3-year overall survival (OS) rate of 75.5 percent among patients with CR.

The international, multicentre, randomized phase III GCIG INTERLACE trial reports significantly higher 5-year progression-free survival (PFS) and overall survival (OS) rates with induction chemotherapy followed by chemoradiotherapy (CRT) vs CRT alone in patients with locally advanced cervical cancer.

High-dose somatostatin analogues (SSAs) can be effective and well-tolerated second-line therapies in neuroendocrine tumours (NETs) progressing on standard-dose SSAs in selected cases, according to Dr Ingrid Mak of the University of Hong Kong, at the 7th Endocrinology, Diabetes & Metabolism Hong Kong Annual Meeting (EDM HK 2024).